Sulfate ion
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Sulfate ion
- Accession Number
- DB14546
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Structure
Structure for Sulfate ion (DB14546)
- Weight
- Average: 96.063
Monoisotopic: 95.951729178 - Chemical Formula
- O4S
- Synonyms
- Sulfate
- Sulfate dianion
- Sulfate(2-)
- Sulfuric acid ion(2-)
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Sulfate ion. Aclidinium The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Aclidinium. Alfentanil The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Alfentanil. Alloin The risk or severity of adverse effects can be increased when Sulfate ion is combined with Alloin. Almasilate The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Almasilate. Aluminium phosphate The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Aluminium phosphate. Aluminum hydroxide The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Aluminum hydroxide. Amantadine The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Amantadine. Amiloride The risk or severity of adverse effects can be increased when Amiloride is combined with Sulfate ion. Amiodarone The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Amiodarone. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Loa Freedom S Capsule 100 g/1001 Oral LOA BIO INC. 2020-11-09 Not applicable US 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Rurina Sulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L) Liquid Topical Nano Bio Tech Co.,Ltd 2017-07-01 Not applicable US Rurina Sulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L) Liquid Topical TELOM-X GENE Co., Ltd. 2017-07-01 Not applicable US Telom-X-gene Sulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L) Liquid Topical TELOM-X GENE Co., Ltd. 2017-07-01 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Loa Freedom S Sulfate ion (100 g/1001) Capsule Oral LOA BIO INC. 2020-11-09 Not applicable US Rurina Sulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L) Liquid Topical Nano Bio Tech Co.,Ltd 2017-07-01 Not applicable US Rurina Sulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L) Liquid Topical TELOM-X GENE Co., Ltd. 2017-07-01 Not applicable US Telom-X-gene Sulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L) Liquid Topical TELOM-X GENE Co., Ltd. 2017-07-01 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- 7IS9N8KPMG
- CAS number
- 14808-79-8
- InChI Key
- QAOWNCQODCNURD-UHFFFAOYSA-L
- InChI
- InChI=1S/H2O4S/c1-5(2,3)4/h(H2,1,2,3,4)/p-2
- IUPAC Name
- sulfate
- SMILES
- [O-]S([O-])(=O)=O
References
- General References
- Not Available
- External Links
- PDB Entries
- 101m / 102m / 103m / 104m / 105m / 106m / 107m / 108m / 109m / 110m … show 21162 more
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Diagnostic Cathartic Colon 1 4 Completed Treatment Inflammatory Bowel Diseases (IBD) / Iron Deficiency 1 4 Not Yet Recruiting Treatment Anemia of Prematurity / Very Low Birth Weight Infant 1 4 Recruiting Treatment Chronic Kidney Disease (CKD) / Kidney Insufficiency, Chronic 1 4 Unknown Status Diagnostic Colonoscopy 1 4 Unknown Status Diagnostic Preeclampsia 1 4 Unknown Status Treatment Deep Neuromuscular Blockade / Magnesium Sulfate / Neuromuscular Blockade / Rocuronium 1 4 Unknown Status Treatment Inflammatory Bowel Diseases (IBD) / Iron Deficiency Anemia (IDA) 1 4 Unknown Status Treatment Iron Deficiency Anemia (IDA) / Iron-Deficiency Anemias / Pregnant State 1 3 Active Not Recruiting Treatment Acute Lymphoblastic Leukaemias (ALL) / Acute Undifferentiated Leukemia (AUL) / Childhood T Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Oral 100 g/1001 Liquid Topical Solution Intravenous 12 g/L - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -0.84 ChemAxon pKa (Strongest Acidic) -3 ChemAxon Physiological Charge -2 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 80.26 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 11.53 m3·mol-1 ChemAxon Polarizability 5.81 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on July 12, 2018 21:40 / Updated on June 12, 2020 16:53